PODCAST · news
Biopharma Morning Coffee
by Pavel Ryzhov
Exactly what it means - get a cup of coffee, listen to a brief rundown of latest biopharma news - but not just in a "here's what happened" way - get extra insights WHY these news matter.
-
1
Biopharma Morning Coffee – Weekly Brief February 26, 2026
Gilead's $7.8B acquisition of Arcellx and its CAR-T therapy anito-cel headlines this week — a PDUFA date of December 2026 signals a major cell therapy outsourcing wave ahead. The FDA also launched its bespoke gene therapy pathway, opening a new regulatory road for gene editing and RNA-based rare disease treatments. Plus: the GLP-1 war heats up as Novo's CagriSema falls to Zepbound, Pfizer licenses a Chinese GLP-1 for $495M, and Astellas bets $1.7B on a masked T-cell engager for prostate cancer.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
Loading similar podcasts...